Radiotherapy Dose for cT1 Esophageal Cancer in Surgical Candidates

Primary Treatment Recommendation for cT1 Disease

The British Journal of Cancer recommends surgical excision as the standard of care for cT1 esophageal cancer in operable patients 1, 2
For early-stage T1 tumors, the Annals of Oncology suggests endoscopic en bloc resection (EMR or ESD) as the initial approach 3, 4
Surgical treatment is specifically recommended for stages I and II disease (localized to the esophagus) by the British Journal of Cancer 1, 2

The British Journal of Cancer states that combined chemoradiotherapy is an alternative to surgery for T1 tumors only in certain specialized institutions 1, 5
The Annals of Oncology recommends considering this approach primarily for patients who are medically unfit for surgery or refuse surgical intervention 2, 6

The Annals of Oncology recommends delivering 50.4 Gy in 28 fractions (1.8 Gy per fraction) or 50 Gy in 25 fractions (2 Gy per fraction) if definitive chemoradiotherapy is selected 4, 6
The standard dosing regimen is 50.4 Gy in 28 fractions delivered over 5 weeks with concurrent cisplatin/5-FU chemotherapy (4 cycles) according to the British Journal of Cancer and Annals of Oncology 1, 5, 2
An alternative regimen is 50 Gy in 25 fractions over 5 weeks with concurrent chemotherapy, as suggested by the Annals of Oncology 4, 6

The Annals of Oncology recommends using intensity-modulated RT (IMRT) or volumetric arc therapy (VMAT) as preferred techniques over 3D conformal RT to minimize dose to critical normal tissues 4, 6
Radiation should be delivered in conventional fractionation (1.8-2.0 Gy per fraction) according to the Annals of Oncology 4, 6, 7

For squamous cell carcinoma, the Annals of Oncology recommends definitive chemoradiotherapy with close surveillance and salvage surgery as a recommended option even in operable patients 4, 6
For adenocarcinoma, patients should proceed to surgery even after complete clinical response to chemoradiotherapy, as watch-and-wait strategies have limited supporting data, according to the Annals of Oncology 3, 6

The British Journal of Cancer recommends combined chemoradiation therapy as the standard treatment for inoperable esophageal cancer, while surgical resection remains the primary approach for early-stage disease with chemoradiation playing important roles in multimodal treatment strategies depending on disease stage and patient factors 8, 9, 10

For early-stage disease, the British Journal of Cancer recommends surgical excision as the primary treatment, and for inoperable patients, combination chemoradiotherapy is the standard treatment 8, 11
For locally advanced disease, the British Journal of Cancer suggests that combined chemoradiation therapy is superior to radiotherapy alone for non-surgical treatment, with level of evidence B 8
For advanced disease without tracheal mucosal invasion, palliative surgery, chemoradiation therapy, or radiotherapy alone are options, according to the British Journal of Cancer 10, 12

The standard chemoradiation regimen includes cisplatin and 5-fluorouracil with concurrent radiation therapy, as recommended by the British Journal of Cancer 8
The Gastroenterology journal notes that the risk of metastasis increases significantly if cancer penetrates into the submucosa, highlighting the importance of accurate staging 11

Combined chemotherapy and radiation therapy is superior to radiation therapy alone for non-surgical treatment of esophageal cancer, with improved local control, decreased distant metastases, and better survival rates, according to the British Journal of Cancer 8
The British Journal of Cancer recommends preoperative chemoradiation therapy for patients with adenocarcinoma of the esophagus or esophagogastric junction, with level of evidence B 8
The Gastroenterology journal suggests that endoscopic therapy represents the standard for patients unfit for other treatments 8, 11
Praxis Medical Insights recommends nutritional support before chemotherapy or radiation therapy 13